폐질환용 AI 의료 영상 소프트웨어 시장 : 시장 예측(2026-2032년)

The AI Medical Imaging Software for Lung Diseases Market is projected to grow by USD 1,336.98 million at a CAGR of 7.92% by 2032.

AI Medical Imaging Software for Lung Diseases: Executive Overview

AI medical imaging software for lung diseases applies machine learning, computer vision, and clinical decision-support techniques to modalities such as chest radiography, computed tomography, and magnetic resonance imaging. Its principal uses include detection support, image triage, quantification of disease patterns, workflow prioritization, and longitudinal monitoring. Adoption is shaped by clinical validation, interoperability, regulatory clearance, cybersecurity, reimbursement, and the ability to integrate safely into radiology and pulmonary-care pathways.

Clinical Workflows Are Shifting from Detection to Integrated Decision Support

The landscape is moving beyond isolated image classification toward tools that support the full diagnostic workflow, including protocol optimization, automated measurements, structured reporting, urgent-case prioritization, and comparison with prior examinations. This shift increases the importance of explainability, calibration across scanners and populations, and human oversight. Effective deployment depends on embedding software into existing picture archiving and communication systems, electronic health records, and multidisciplinary care processes rather than adding another disconnected interface.

Artificial Intelligence Is Increasing Throughput While Raising Governance Requirements

Artificial intelligence can help clinicians manage high imaging volumes, identify subtle findings, reduce repetitive measurement work, and standardize interpretation support. Its cumulative effect is strongest where data are well curated and workflows are clearly defined. At the same time, performance can vary with population characteristics, acquisition protocols, image quality, and disease prevalence. Leaders therefore need continuous monitoring for drift, transparent documentation of intended use, bias assessment, privacy safeguards, and clear rules assigning responsibility for final clinical decisions.

Regional Conditions Determine the Pace and Form of Adoption

North America benefits from mature digital infrastructure, active clinical validation, and established regulatory pathways, while Latin America is influenced by uneven access to imaging capacity, connectivity, and specialist expertise. Europe emphasizes privacy, conformity assessment, interoperability, and health-system evidence across diverse national settings. The Middle East is investing in advanced healthcare infrastructure and centralized services, whereas Africa faces significant differences in equipment availability, connectivity, workforce capacity, and data representativeness. Asia-Pacific combines advanced innovation ecosystems with substantial variation in healthcare access, regulatory maturity, and urban-rural service distribution.

Economic and Security Alliances Shape Procurement and Interoperability Priorities

ASEAN markets commonly prioritize scalable deployment across diverse health systems and cross-border interoperability. BRICS members reflect varied public-sector capacity, domestic technology priorities, and regulatory approaches. The European Union places strong emphasis on privacy, safety, conformity, and interoperable data environments. G7 systems generally have extensive clinical infrastructure but face evidence, workforce, and integration requirements. GCC countries often support centralized digital-health programs and specialist-care expansion. NATO members also give heightened attention to cyber resilience, continuity of operations, secure infrastructure, and supply-chain risk.

Country Contexts Create Distinct Deployment Opportunities and Constraints

Australia and Canada must address dispersed populations and equitable access across large territories. Brazil, Mexico, India, and South Africa face substantial variation in infrastructure, specialist availability, and public-private delivery models. China, Japan, and South Korea combine advanced technical capabilities with distinctive regulatory, procurement, and data-governance environments. France, Germany, Italy, Spain, and the United Kingdom operate within mature healthcare systems where clinical evidence, workflow integration, privacy, and reimbursement are central adoption considerations. Russia's deployment environment is shaped by domestic infrastructure, regulatory conditions, and access to specialized technology. Across the United States, scale of care delivery, regulatory compliance, interoperability, and liability management remain major implementation considerations.

Prioritize Validated Use Cases, Interoperability, and Continuous Clinical Oversight

Industry leaders should begin with clearly defined clinical problems, such as urgent-case triage or reproducible lesion quantification, and evaluate outcomes against clinically meaningful measures rather than technical accuracy alone. They should require representative local validation, subgroup testing, prospective workflow assessment, and transparent documentation of limitations. Procurement should include interoperability standards, cybersecurity controls, auditability, data-retention rules, model-update governance, and service-level expectations. Successful programs also invest in clinician training, escalation procedures, post-deployment monitoring, and structured feedback loops linking radiologists, pulmonologists, technologists, information-technology teams, and patients.

Methodology: Evidence-Based Assessment of Clinical, Technical, and System Factors

This executive summary uses a structured qualitative assessment of the AI medical imaging software landscape for lung diseases. The assessment considers peer-reviewed clinical evidence, regulatory and safety principles, healthcare digitization conditions, imaging workflow requirements, interoperability practices, privacy and cybersecurity expectations, and country- and region-level health-system characteristics. Findings are synthesized thematically across applications, adoption barriers, implementation requirements, and governance considerations. No market estimates, market shares, forecasts, or company-specific claims are used.

Responsible Integration Will Define Long-Term Value

AI medical imaging software can strengthen lung-disease pathways when it is clinically validated, locally appropriate, interoperable, and governed as a continuously monitored medical technology. The strongest results will come from implementations that augment-not replace-professional judgment and that connect technical performance with measurable improvements in timeliness, consistency, access, and patient safety. Regional and country differences make adaptable deployment models essential, while robust evidence and transparent accountability remain the foundation for sustainable use.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. AI Medical Imaging Software for Lung Diseases Market, by Component

• 7.1. Introduction
• 7.2. Services
  • 7.2.1. Managed Services
  • 7.2.2. Professional Services
• 7.3. Software
  • 7.3.1. Integrated Platform
  • 7.3.2. Standalone Software

8. AI Medical Imaging Software for Lung Diseases Market, by Modality

• 8.1. Introduction
• 8.2. Computed Tomography
• 8.3. Magnetic Resonance Imaging
• 8.4. Positron Emission Tomography
• 8.5. X Ray

9. AI Medical Imaging Software for Lung Diseases Market, by Disease Type

• 9.1. Introduction
• 9.2. Chronic Obstructive Pulmonary Disease
• 9.3. Lung Cancer
• 9.4. Pneumonia
• 9.5. Tuberculosis

10. AI Medical Imaging Software for Lung Diseases Market, by Application

• 10.1. Introduction
• 10.2. Diagnostics
• 10.3. Monitoring
• 10.4. Screening
• 10.5. Surgical Assistance

11. AI Medical Imaging Software for Lung Diseases Market, by End User

• 11.1. Introduction
• 11.2. Ambulatory Care
• 11.3. Diagnostic Centers
• 11.4. Hospitals
• 11.5. Research Institutes

12. AI Medical Imaging Software for Lung Diseases Market, by Deployment

• 12.1. Introduction
• 12.2. Cloud Based
  • 12.2.1. Hybrid Cloud
  • 12.2.2. Private Cloud
  • 12.2.3. Public Cloud
• 12.3. On Premise
  • 12.3.1. Edge Server
  • 12.3.2. Private Data Center

13. AI Medical Imaging Software for Lung Diseases Market, by Region

• 13.1. Introduction
• 13.2. Asia-Pacific
• 13.3. North America
• 13.4. Latin America
• 13.5. Europe
• 13.6. Middle East
• 13.7. Africa

14. AI Medical Imaging Software for Lung Diseases Market, by Group

• 14.1. Introduction
• 14.2. ASEAN
• 14.3. GCC
• 14.4. European Union
• 14.5. BRICS
• 14.6. G7
• 14.7. NATO

15. AI Medical Imaging Software for Lung Diseases Market, by Country

• 15.1. Introduction
• 15.2. United States
• 15.3. Canada
• 15.4. Mexico
• 15.5. Brazil
• 15.6. United Kingdom
• 15.7. Germany
• 15.8. France
• 15.9. Russia
• 15.10. Italy
• 15.11. Spain
• 15.12. China
• 15.13. India
• 15.14. Japan
• 15.15. Australia
• 15.16. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. Market Concentration Analysis, 2025
  • 16.2.1. Concentration Ratio (CR)
  • 16.2.2. Herfindahl Hirschman Index (HHI)
• 16.3. Recent Developments & Impact Analysis, 2025
• 16.4. Product Portfolio Analysis, 2025
• 16.5. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Aidoc Ltd.
• 17.2. Annalise.ai Pty Ltd
• 17.3. Arterys, Inc.
• 17.4. GE HealthCare Inc.
• 17.5. Infervision Technology Co., Ltd.
• 17.6. Koninklijke Philips N.V.
• 17.7. Lunit Inc.
• 17.8. Optellum Ltd.
• 17.9. Oxipit Labs UAB
• 17.10. Qure.ai Technologies Pvt. Ltd.
• 17.11. Riverain Technologies, LLC
• 17.12. Siemens Healthineers AG
• 17.13. Thirona NV
• 17.14. VIDA Diagnostics, Inc.
• 17.15. Zebra Medical Vision Ltd.

18. Key Experts